TOP > 外国特許検索 > CANCER TREATMENT AGENT

CANCER TREATMENT AGENT NEW

外国特許コード F190009697
整理番号 (P15-099(2))
掲載日 2019年1月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP037473
国際公開番号 WO 2018074451
国際出願日 平成29年10月17日(2017.10.17)
国際公開日 平成30年4月26日(2018.4.26)
優先権データ
  • 特願2016-203793 (2016.10.17) JP
  • 特願2017-061056 (2017.3.27) JP
発明の名称 (英語) CANCER TREATMENT AGENT NEW
発明の概要(英語) The purpose of the present invention is to provide a cancer treatment agent that is characterized by combining the active ingredient caffeine citrate with an anticancer agent which is an active ingredient. Specifically provided is a cancer treatment agent having the anticancer agent cisplatin, gemcitabine, or adriamycin as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Bone sarcoma (osteosarcoma) is, in the young 10 decades primarily malignant bone tumors as a predilection for the original generation is of the most frequent, the cause is unknown.The occurrence frequency is 1 to 100 million people in Japan the rate of occurrence of a person (person 130 person 260 from the year 1) is called.In the past was the only treatment options of the amputation age, bone sarcoma and 2 - year survival rate is 15-20%, a very poor prognosis of the disease.However, the introduction of chemical therapy, and surgical therapy progress with the development of image diagnosis, the current 5 - year survival rate is greater than or equal to 70% (non-patent document 1) respectively.The inventors of the present invention, 'caffeine of the combination chemotherapy' has been disclosed.By this modality, no transition to the initial visit to complete the treatment in the example, 5 - year survival rate is 89% and is greatly improved, improving the prognosis is still insufficient, it is necessary to further improve the effect of the treatment (non-patent document 2).In addition, with regard to transition of the initial visit or any recurrence in the example, 10-30% and 5 - year survival rate is, in the past year is 40, not a significant improvement, further improvement of the effect of the treatment also in this respect is considered necessary (non-patent document 3).
Is soft (soft sarcoma) sarcoma, leiomyosarcoma, fibrosarcoma, fat sarcoma, Rhabdomyosarcoma such as the various classification.Each has different properties, a very high degree of rarity.Ewing sarcoma of the outer bone, except rhabdosarcoma in non-small circular sarcoma cells, limb development and stage III is not limited to, surgery alone is about 35% 10 - year survival rate has been reported (Non-Patent Document 4).Further, the progress of high-grade effects of chemotherapy for example soft tissue sarcoma is, has been reported in the response rate and 30-40%, compared to the soft tissue sarcoma is a bone, a disease retardment to further improving the prognosis (Non-Patent Document 5-7).The current standard of treatment methods are soft sarcoma, grade, tumor type and depending on the condition of the patient, preoperative chemotherapy and surgery and post-operative chemotherapy (wide resection) and a combination of the base.Chemical therapy, such as doxorubicin and cisplatin was used Polychemotherapeutic therapy.As described above, the treatment method, treatment effect is not necessarily satisfactory, because the height of the soft tissue sarcoma rare, the development of new drugs is a problem that does not easily occur.
As mentioned above, in various cancer types effect can be produced, conventional chemotherapy has a therapeutic effect is more robust than the new therapeutic agents has been desired.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY
  • 発明者(英語)
  • TSUCHIYA,Hiroyukio
  • TAKEUCHI,Akihiko
  • ABE,Kensaku
  • YAMAMOTO,Norio
  • HAYASHI,Katsuhiro
国際特許分類(IPC)
(有)金沢大学ティ・エル・オーは、金沢大学の研究者の出願特許を産業界へ技術移転することを主目的として、金沢大学の教官の出資により設立された技術移転機関です。
ご興味のある方は、下記「問合せ先」へ整理番号と共にご連絡願います。
なお、既に活用のお申し込み・お打合わせ等の段階に入っている場合もございますので、予めご承知おきください。

PAGE TOP

close
close
close
close
close
close